ArticleEmerging microbes & infections2026
Consensus H3N2 HA immunogens incorporating key antigenic mutations elicit broad-spectrum neutralizing responses.
Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seasonal influenza A/H3N2 poses a significant public health burden due to its rapid antigenic evolution, necessitating frequent vaccine updates. This study systematically analysed the antigenic evolution of 14 H3N2 vaccine strains (2000-2022) using pseudovirus-based neutralization assays and antigenic cartography. Vaccine strains exhibited cross-neutralization patterns, with higher reactivity among strains from adjacent years, forming six antigenic clusters. Key amino acid mutations (e.g. 144K, 189N) were identified as critical drivers of antigenic variation, with clustering-specific effects on neutralization sensitivity. Based on these findings, a consensus HA immunogen (consensus up-HA) was designed by combining mutations at key sites. This immunogen demonstrated broad-spectrum neutralization against pseudoviruses representing circulating strains from 2011 to 2024, including recent variants. These results highlight the potential of targeted HA modifications to develop broadly cross-reactive H3N2 vaccine candidate, offering broader and more durable neutralizing activity against evolving H3N2 strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.